Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
Viridian Therapeutics, Inc.\DE (VRDN)
A forensic read on Viridian Therapeutics, Inc.\DE built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
2.7
Altman Z-score
Watch
Earnings quality
4
Forensic signals
-60.7%
ROE
$1.8B
Market cap
Viridian Therapeutics, Inc.\DE earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is 2.7, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by receivables vs revenue.
What the filings flag
9d DSOReceivables vs revenue.Days sales outstanding moved from 1 to 9 days FY2018→FY2019 (receivables +350% vs revenue -47%). Receivables are outrunning sales — a flag for aggressive revenue recognition or slipping collections.
-97%Return on invested capital.Return on invested capital is -97% and steady — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+386.1%/yrShare-count dilution.Diluted share count changed +1158% over the last 3 years to FY2023 (+386.1%/yr). The count is GROWING — existing holders are being diluted. That's ~386.1% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2020 has been diluted ~1158%.
63% of revStock-based comp load.Stock-based compensation ran 63% of revenue in FY2025. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
Key fundamentals
Net Margin-483.6%
Debt / Equity0.04x
Free Cash Flow$-276.9M
Latest Revenue$70.8M
Return on Equity-47.4%
Revenue Growth YoY+23359.9%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Viridian Therapeutics, Inc.\DE:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about VRDN's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown